Danish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Side 1 fra 17 resultater
A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
This phase II study in recurrent high-grade glioma evaluated the response rate, toxicities, and time to treatment failure of high-dose carboplatin modulated by a 24-h infusion of thymidine (75 g/m(2)). The trial was based on preclinical data and a prior phase I study ( J. Clin. Oncol. 17, 2922-2931,
Clinical phase I-II and pharmacokinetic study of high-dose thymidine given by continuous intravenous infusion.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
High-dose thymidine (dThd) was given to 12 patients with advanced hematological and solid tumors. The dose schedule used was 75 g/sq m/day, given i.v. continuously for 5 days or more. Myelosuppression, especially leukopenia, was the dose-limiting toxicity. Nonhematological toxicities affected the
Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
OBJECTIVE
To evaluate the biologic interactions and toxicities of carboplatin combined with a 24-hour infusion of thymidine 75 mg/m(2) in a phase I trial.
METHODS
Thirty-two patients with cancer refractory to conventional therapy were treated. The first set of patients (n = 7) received thymidine
Modulation of 1-beta-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Twenty-seven patients with acute leukemia have been treated by sequential 6-day courses of thymidine (30 g/m2 by i.v. continuous infusion, days 1 and 4) and 1-beta-D-arabinofuranosylcytosine (ara-C) (200 mg/m2 by i.v. continuous infusion, days 2,3,5, and 6). Of 25 evaluable patients 4 achieved a
Effect of high-dose thymidine infusions in patients with mycosis fungoides.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
The antitumor effect of thymidine has been demonstrated in patients with leukemia and lymphoma. This report summarizes the treatment of three patients with mycosis fungoides, a chronic T-cell lymphoma. Four courses of thymidine (75 g/m2/day) were administered by continuous infusion for 4-7 days.
Intrathecal cytostatic therapy of meningeal carcinomatosis. Autoradiographic investigations of the CSF cells.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Autoradiographic investigations with 3H-thymidine were performed on cerebrospinal fluid (CSF) cells from a case of meningeal carcinomatosis following carcinoma of the breast. The cells were found to be anaplastic histologically. Within a period of 12 days 3 X 25 mg methotrexate were injected into
Telbivudine for the management of chronic hepatitis B virus infection.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
BACKGROUND
Telbivudine (LdT) is an L-nucleoside that is structurally related to lamivudine. It is highly selective for hepatitis B virus (HBV) and inhibits viral DNA synthesis. LdT was approved by the US Food and Drug Administration on October 25, 2006, for the treatment of chronic HBV infection in
A novel mutation of the succinate dehydrogenase B gene in a Korean family with pheochromocytoma.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Pheochromocytoma is a tumor that originates from the adrenal cortex and sympathetic chains. Most pheochromocytomas are sporadic, whereas others occur as hereditary syndromes. Familial pheochromocytoma has been frequently found in association with various mutations in genes of the succinate
5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
In an attempt to increase the clinical activity of 5-fluorouracil (5-FU) by blocking the thymidine salvage pathway, 15 patients with refractory metastatic breast cancer (MBC) were treated with oral dipyridamole (D): 75 mg p.o. q.i.d. and 5-FU: 400 mg/m2 i.v. by bolus for 5 consecutive days, every 28
Mitochondrial neurogastrointestinal encephalopathy: a clinicopathological mimic of Crohn's disease.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Zidovudine toxicity. Clinical features and management.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Zidovudine is a dideoxynucleoside analogue of thymidine. It acts by interfering with viral reverse transcriptase, thereby inhibiting human immunodeficiency virus (HIV) replication. Zidovudine has been shown in clinical trials to prolong survival of patients with acquired immune deficiency syndrome
Intracavitary chemotherapy with 5-fluoro-2'-deoxyuridine (FdUrd) in malignant brain tumors.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
BACKGROUND
After completing basic research on the anti-tumor effects and neurotoxicity of 5-fluoro-2'-deoxyuridine (FdUrd) and the balance of thymidine kinase and thymidine phosphorylase activities and confirming the safety of intrathecal FdUrd administration in a previous clinical study of
Spontaneous cerebellar hemorrhage associated with a novel Notch3 mutation.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
A 55-year-old woman with no significant medical history presented with an acute onset severe headache. A non-enhanced CT scan of the head revealed a right cerebellar hemorrhage. Investigation for etiology of the hemorrhage included an MRI showing extensive subcortical ischemic disease and also
Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
In previous in vitro studies, the authors showed that phytohemagglutinin (PHA) stimulated peripheral blood lymphocytes (PBL) from cancer patients to generate cells that were lytic for fresh autologous tumor but not for lymphocytes or lymphoblasts. Thus, after IRB approval, a phase I clinical
Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist.
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Stromal cell-derived factor-1 (SDF-1/CXCL12) plays a key regulatory role in the trafficking of hematopoietic cells. AMD3100 is a specific antagonist of the binding of SDF-1 to its receptor, CXCR4. This phase I study assessed the hematological effects, pharmacokinetics, and safety of administration
Den mest komplette database med medicinske urter understøttet af videnskab
- Arbejder på 55 sprog
- Urtekurer, der understøttes af videnskab
- Urtegenkendelse ved billede
- Interaktivt GPS-kort - tag urter på stedet (kommer snart)
- Læs videnskabelige publikationer relateret til din søgning
- Søg medicinske urter efter deres virkninger
- Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter
Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod.
* Al information er baseret på offentliggjort videnskabelig forskning
